following an abbreviated submission:
filgotinib (Jyseleca®) is accepted for use within NHSScotland.
Indication under review: for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
Filgotinib provides an additional treatment choice in the therapeutic class of janus kinase (JAK) inhibitors.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice634KB (PDF)
Medicine details
- Medicine name:
- filgotinib (Jyseleca)
- SMC ID:
- SMC2467
- Indication:
For treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
- Pharmaceutical company
- Galapagos Biotech Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 May 2022